EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial

Tetsuya Ishikawa iD, Masahiro Natsuaki, Hirotoshi Watanabe iD, Takeshi Morimoto iD, Ko Yamamoto iD, Yuki Obayashi iD, Ryusuke Nishikawa iD, Kenji Ando iD, Satoru Suwa iD, Tsuyoshi Isawa iD, Hiroyuki Takenaka, Ruka Yoshida iD und 10 weitere

Circulation: Cardiovascular Interventions · 2025-07 · 18 (7)

DOI: 10.1161/circinterventions.124.015197 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2025-07. Verfasst von Tetsuya Ishikawa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Japan (T. Ishikawa). Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Coronary Artery Disease, Hemorrhage, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The effects of the aspirin-free strategy on bleeding and cardiovascular events were unknown in patients with high bleeding risk (HBR), with or without acute coronary syndrome (ACS), undergoing percutaneous coronary intervention. METHODS: We conducted a subgroup analysis stratified by ACS among patients with HBR in the STOPDAPT-3 trial (Short and Optimal Duration of Dual Antiplatelet Therapy-3), which randomly compared no-aspirin (prasugrel monotherapy) with dual antiplatelet therapy (DAPT) in patients with ACS and HBR. RESULTS: There were 3258 patients with HBR, including 1803 ACS and 1455 non-ACS patients. The effects of no-aspirin compared with DAPT at 1 month after percutaneous coronary intervention were not significant for major bleeding regardless of ACS or non-ACS (7.3% versus 7.9%; hazard ratio [HR], 0.91 [95% CI, 0.65–1.28], and 3.1% versus 2.9%; HR, 1.06 [95% CI, 0.58–1.93]; P interaction=0.66). There was a numerically higher risk in the no-aspirin group relative to the DAPT group for a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke in patients with ACS, but not in patients with non-ACS (7.9% versus 5.8%; HR, 1.39 [95% CI, 0.97–1.99], and 2.4% versus 3.0%; HR, 0.78 [95% CI, 0.41–1.47]; P interaction=0.12). There was a significant treatment-by-subgroup interaction for myocardial infarction (1.6% versus 0.3%; HR, 4.57 [95% CI, 1.31–15.89], and 1.4% versus 1.8%; HR, 0.78 [95% CI, 0.34–1.77]; P interaction=0.02). CONCLUSIONS: The aspirin-free strategy compared with the DAPT strategy failed to reduce major bleeding in patients with HBR irrespective of ACS. There was a signal of the excess risk of the aspirin-free strategy relative to the DAPT strategy for cardiovascular events, myocardial infarction in particular, in patients with ACS, but not in patients with non-ACS. The aspirin-free strategy may be considered as a potential treatment option after percutaneous coronary intervention in patients with non-ACS. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04609111.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeCoronary Artery DiseaseHemorrhagePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPrasugrel HydrochlorideAgedFemaleHumansMaleMiddle AgedAspirinDual Anti-Platelet TherapyRisk AssessmentRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

hemorrhagehumansischemic strokestentsthrombosis

Substanzen

AspirinPlatelet Aggregation InhibitorsPrasugrel Hydrochloride

Autor:innen und Institutionen

  • Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Japan (T. Ishikawa).
  • Department of Cardiovascular Medicine, Saga University, Japan (M.N.).
  • Division of Cardiology, Hirakata Kohsai Hospital, Japan (H.W., H.T., T. Kimura).
  • Department of Clinical Epidemiology, Hyogo College of Medicine, Japan (T.M.).
  • Department of Cardiology, Kokura Memorial Hospital, Japan (K.Y., K.A.).
  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (Y.O., R.N., K.O.).

ORCID-Profile: Tetsuya Ishikawa, Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, Ruka Yoshida, Gaku Nakazawa, Itsuro Morishima, Hirosada Yamamoto, Koh Ono, Takeshi Kimura

Zitieren

APA

Ishikawa, T., Natsuaki, M., Watanabe, H., Morimoto, T., Yamamoto, K., Obayashi, Y., Nishikawa, R., Ando, K., Suwa, S., Isawa, T., Takenaka, H., Yoshida, R., Suzuki, H., Nakazawa, G., Kusuyama, T., Morishima, I., Hojo, S., Tsutsumi, J., Yamamoto, H., …, & Kimura, T. (2025). Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial. Circulation: Cardiovascular Interventions, 18(7). https://doi.org/10.1161/circinterventions.124.015197

Vancouver

Ishikawa T, Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, et al. Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial. Circulation: Cardiovascular Interventions. 2025;18(7). doi:10.1161/circinterventions.124.015197

BibTeX
@article{Ishikawa2025,
  author = {Ishikawa, Tetsuya and Natsuaki, Masahiro and Watanabe, Hirotoshi and Morimoto, Takeshi and Yamamoto, Ko and Obayashi, Yuki and Nishikawa, Ryusuke and Ando, Kenji and Suwa, Satoru and Isawa, Tsuyoshi and Takenaka, Hiroyuki and Yoshida, Ruka and Suzuki, Hiroshi and Nakazawa, Gaku and Kusuyama, Takanori and Morishima, Itsuro and Hojo, Syun and Tsutsumi, Joshi and Yamamoto, Hirosada and Ueda, Hiroshi and Ono, Koh and Kimura, Takeshi},
  title = {Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {7},
  doi = {10.1161/circinterventions.124.015197}
}
Kostenlos starten →